{
    "id": 1635,
    "fullName": "TP53 negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TP53 negative indicates a lack of the TP53 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "negative",
    "createDate": "09/09/2014",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11742,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53-null non-small cell lung carcinoma cells demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",
            "molecularProfile": {
                "id": 1647,
                "profileName": "TP53 negative"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 609,
                    "pubMedId": 22862161,
                    "title": "Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22862161"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 992,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a pilot trial, TP53-negative breast cancer patients demonstrated increased survival following treatment with Avastin (bevacizumab) in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel), compared to patients with TP53-positive tumors (PMID: 21399868).",
            "molecularProfile": {
                "id": 1647,
                "profileName": "TP53 negative"
            },
            "therapy": {
                "id": 1421,
                "therapyName": "Bevacizumab + Docetaxel + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 658,
                    "pubMedId": 21399868,
                    "title": "p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21399868"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY2940680 treatment of Ptch+/- p53-/- transgenic mice, which spontaneously develop medulloblastoma, resulted in significant anti-tumor activity (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).",
            "molecularProfile": {
                "id": 1975,
                "profileName": "PTCH1 neg TP53 neg"
            },
            "therapy": {
                "id": 1587,
                "therapyName": "Taladegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 883,
                    "pubMedId": null,
                    "title": "Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling",
                    "url": "https://cancerres.aacrjournals.org/content/71/8_Supplement/2819"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9324,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced inhibition of anchorage-independent growth compared to single agent in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 inhibited anchorage-independent growth in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth, but did not induce cell death in prostate cancer cells with high Myc expression and no TP53 expression in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26815,
                "profileName": "MYC over exp TP53 neg"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13091,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TP53/MDM2/MDM4-null acute lymphocytic leukemia (ALL) cell line demonstrated decreased sensitivity to AQ-101 compared to ALL cell lines with wild-type TP53 and MDM2 overexpression in culture (PMID: 29282301).",
            "molecularProfile": {
                "id": 29006,
                "profileName": "MDM2 neg MDM4 neg TP53 neg"
            },
            "therapy": {
                "id": 6682,
                "therapyName": "AQ-101",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10752,
                    "pubMedId": 29282301,
                    "title": "Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29282301"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1647,
            "profileName": "TP53 negative",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1975,
            "profileName": "PTCH1 neg TP53 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26815,
            "profileName": "MYC over exp TP53 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29006,
            "profileName": "MDM2 neg MDM4 neg TP53 neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}